A versatile polyion complex can intelligently respond to a tumor microenvironment to eliminate tumor stem cells for enhanced lung cancer targeted therapy
Source abstract
Abstract
Poor prognosis in lung cancer has been proved to be associated with the presence of lung cancer stem cells (LCSCs). Similar to bulk cancer cells and always existing in the interior of a solid tumor, there are also insurmountable barriers for the elimination of CSCs. To overcome these drawbacks, a versatile polyion complex was rationally designed, which can respond to a tumor microenvironment and exhibits a size-variable property, which allows it to possess remarkable tumor penetration capability and to accumulate around LCSCs. Protein tyrosine kinase 7 (PTK7) antibody mediated active targetability can facilitate the cellular uptake of triphenylphosphine-docetaxel (TD) and microRNA-31(miR-31) and the breakage of the disulfide bond can also enhance intracellular drug release. TD possesses a favorable apoptosis-inducing effect via a mitochondria pathway, while miR-31 could significantly regulate the MET-PI3K-Akt signaling pathway to exert the capability to eliminate LCSCs. APSP/HA might support new insights into LCSC eradiation in cancer management.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Cells and Metastasis · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy
Shenyang Pharmaceutical University
Shenyang
P.R. China
Oncology Department
Affiliated Hongqi Hospital of Mudanjiang Medical University
Mudanjiang
China
College Pharmacy of Jiamusi University
Jiamusi
PR China
Funding
National Natural Science Foundation of China
References (35)
Show source-provided references
1. Hirsch · Lancet · 2017 · 389 · 29910.1016/S0140-6736(16)30958-8 ↗
2. Loibl · Lancet · 2017 · 389 · 241510.1016/S0140-6736(16)32417-5 ↗
3. Rustin · Lancet · 2011 · 377 · 38010.1016/S0140-6736(11)60126-8 ↗
4. Wang · Lancet · 2018 · 391 · 65910.1016/S0140-6736(17)33108-2 ↗
5. Berns · Cell · 2005 · 121 · 81110.1016/j.cell.2005.06.004 ↗
6. Shackleton · Cell · 2009 · 138 · 82210.1016/j.cell.2009.08.017 ↗
7. Su · Cell · 2018 · 172 · 84110.1016/j.cell.2018.01.009 ↗
8. Nakod · Cancer Lett. · 2018 · 429 · 4110.1016/j.canlet.2018.05.007 ↗
9. Qiang · Cancer Lett. · 2009 · 279 · 1310.1016/j.canlet.2009.01.016 ↗
10. Stopschinski · Cancer Lett. · 2013 · 338 · 3210.1016/j.canlet.2012.05.033 ↗
11. Bai · Cancer Treat. Rev. · 2018 · 69 · 15210.1016/j.ctrv.2018.07.004 ↗
12. Hu · Cancer Lett. · 2018 · 423 · 4710.1016/j.canlet.2018.02.036 ↗
13. Lin · Cancer Lett. · 2018 · 438 · 16510.1016/j.canlet.2018.09.022 ↗
14. Chen · Mol. Pharm. · 2016 · 13 · 274910.1021/acs.molpharmaceut.6b00352 ↗
15. Guo · ACS Appl. Mater. Interfaces · 2015 · 7 · 2395810.1021/acsami.5b06523 ↗
16. Song · ACS Appl. Mater. Interfaces · 2018 · 10 · 702210.1021/acsami.8b01633 ↗
17. Tang · ACS Appl. Mater. Interfaces · 2017 · 9 · 2349710.1021/acsami.7b06393 ↗
18. Alguacil-Núñez · Crit. Rev. Oncol. Hematol. · 2018 · 125 · 10210.1016/j.critrevonc.2018.02.015 ↗
19. W. S. Heng , R.Gosens and F. A. E.Kruyt , Biochem. Pharmacol. , 2019 160 121133
20. Liu · Biomaterials · 2017 · 149 · 6310.1016/j.biomaterials.2017.09.030 ↗
21. Gao · Cell · 2012 · 150 · 76410.1016/j.cell.2012.06.035 ↗
22. Zhang · Cell · 2012 · 148 · 25910.1016/j.cell.2011.11.050 ↗
23. Banerjee · J. Med. Chem. · 2017 · 60 · 130910.1021/acs.jmedchem.6b01270 ↗
24. Kumar · Anal. Chem. · 2018 · 90 · 1206710.1021/acs.analchem.8b02879 ↗
25. Usacheva · Mol. Pharm. · 2014 · 11 · 318610.1021/mp5003619 ↗
26. Liu · Adv. Funct. Mater. · 2019 · 180642910.1002/adfm.201806429 ↗
27. X. Sun , J.Zhang , C.Yang , Z.Huang , M.Shi , S.Pan , H.Hu , M.Qiao , D.Chen and X.Zhao , ACS Appl. Mater. Interfaces , 2019 11 1186511875
28. Liang · ACS Appl. Mater. Interfaces · 2016 · 8 · 1013610.1021/acsami.6b00668 ↗
29. Huo · Carbohydr. Polym. · 2017 · 171 · 17310.1016/j.carbpol.2017.05.017 ↗
30. Zhang · Cancer Res. · 2016 · 76 · 720810.1158/0008-5472.CAN-16-1681 ↗
31. Damelin · Sci. Transl. Med. · 2017 · 9 · eaag261110.1126/scitranslmed.aag2611 ↗
32. Chunying · Anti-Cancer Agents Med. Chem. · 2016 · 16 · 50110.2174/1871520615666150824152353 ↗
33. Zhang · Drug Delivery · 2018 · 25 · 72310.1080/10717544.2018.1446475 ↗
34. Li · Biomaterials · 2015 · 57 · 110.1016/j.biomaterials.2015.04.009 ↗
35. Shi · Int. J. Nanomed. · 2018 · 13 · 688510.2147/IJN.S180119 ↗